Therapeutic Enoxaparin Dosing in Obesity
Annals of Pharmacotherapy · 2025-03 · 59 (3) · 262-276
DOI: 10.1177/10600280241256351 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 19.06.2024. Verfasst von Marcelle Appay und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Enoxaparin, Obesity, Anticoagulants. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: australian government.
Abstract (Originalsprache)
Objective
This review aims to systematically summarize the available data on efficacy and safety of therapeutic enoxaparin in obese patients and to identify gaps to guide future research. Data Sources: Medline and Embase were systematically searched for eligible studies (last searched December 20, 2023). Studies were included if they reported on therapeutic dosing regimens, adverse bleeding, thrombotic outcomes, or antifactor Xa (AFXa) monitoring in obese adult patients. Study Selection and Data Extraction: The systematic review management tool Covidence was used to manage the study selection and data extraction process. The reference list from eligible studies was screened to determine any additional eligible studies. Data Synthesis: Sixteen studies were included in the analysis. Studies used a variety of doses, indications, and study designs making comparison difficult. Twelve studies reported the incidence of thrombotic events (median = 1.3% [interquartile range [IQR] = 0.3%-2.3%]) and all studies reported the incidence of bleeding events (median = 5.7% [IQR = 2.4%-14.5%]). Two of the 8 studies analyzing the influence of weight/body mass index (BMI) or dose per kg on AFXa levels reported statistically significant results. One study concluded that BMI did not affect achievement of target AFXa levels. However, the second study found that dosing using actual body weight was an independent predictor of supratherapeutic AFXa levels in the obese population. Relevance to Patient Care and Clinical Practice: This is the first comprehensive review with a focus on therapeutic dosing of enoxaparin in obesity and has been conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Seven of the included studies were published since 2018 indicating that new evidence on this topic is emerging.
Conclusion
There was inadequate evidence to support an optimal dosing strategy in obese patients due to the heterogeneity of the studies. The AFXa monitoring may be appropriate to guide dosing in this population. Further research is required to determine a suitable dosing regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
- Department of Pharmacy, John Hunter Hospital, Newcastle, NSW, Australia.
- School of Medicine, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
- Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Sydney, NSW, Australia.
- Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
- Department of Pharmacy, Westmead Hospital, Sydney, NSW, Australia.
ORCID-Profile: Marcelle Appay
Förderung
- australian government
Zitieren
APA
Appay, M., Kharadi, S., Nanayakkara, S., Ryu, J. S., Pasalic, L., & Alffenaar, J. W. (2025). Therapeutic Enoxaparin Dosing in Obesity. Annals of Pharmacotherapy, 59(3), 262-276. https://doi.org/10.1177/10600280241256351
Vancouver
Appay M, Kharadi S, Nanayakkara S, Ryu JS, Pasalic L, Alffenaar JW. Therapeutic Enoxaparin Dosing in Obesity. Annals of Pharmacotherapy. 2025;59(3):262-276. doi:10.1177/10600280241256351
BibTeX
@article{Appay2025,
author = {Appay, Marcelle and Kharadi, Shreyas and Nanayakkara, Sajani and Ryu, Ji Sang and Pasalic, Leonardo and Alffenaar, Jan-Willem},
title = {Therapeutic Enoxaparin Dosing in Obesity},
journal = {Annals of Pharmacotherapy},
year = {2025},
volume = {59},
number = {3},
pages = {262--276},
doi = {10.1177/10600280241256351}
}
EUVIMED